Clinical-stage biotechnology developer INmune Bio (Nasdaq: INMB) and integrated quantum photonics vendor Quantum Computing Inc. (Nasdaq: QUBT) have entered into a commercial collaboration to apply quantum optimization and artificial intelligence to drug discovery. Marking QCi’s first commercial deployment within the biopharmaceutical sector, the project utilizes QCi’s room-temperature Dirac-3S quantum optimization machine to analyze multi-trial clinical datasets and identify secondary disease indications for INmune Bio’s neuroinflammation therapeutic, XPro.
| INmune Bio & QCi Quantum Optimization Engagement Profile | ||
|---|---|---|
| System Dimension | Technical Platform | Operational & Clinical Focus |
| Quantum Hardware | QCi Dirac-3S Entropy Quantum Machine | Nanophotonic optimizer operating at room temperature and low power, addressing optimization problems scaling to nearly 10,000 variables. |
| Investigational Biologic | XPro™ (XPro1595 / pegipanermin) | Dominant-negative biologic targeting soluble tumor necrosis factor (sTNF) to treat neuroinflammation without compromising systemic immunity. |
| Analytical Objective | High-dimensional biomarker and cohort mapping | Evaluates patient response patterns across four completed clinical trials and biomedical databases to uncover shared disease mechanisms. |
| Validation Framework | Classical statistical & machine learning benchmarks | Directly compares Dirac-3S solution quality and runtime against standard classical optimization and statistical baselines. |
| Clinical Target | Rare and pediatric disease indications | Identifies indication expansions suitable for rapid trial timelines and potential eligibility for FDA Priority Review Vouchers (PRVs). |
Drug repurposing and biomarker identification require searching combinatorial spaces where biological responses are governed by non-linear relationships across thousands of genomic and proteomic variables. By mapping these multidimensional interaction graphs into the mathematical formulations native to QCi’s platform, the workflow seeks to identify which adjacent disease pathways correlate with the specific inflammatory proteins targeted by the biologic.
Operating without dilution refrigerators or cryogenic support systems, the Dirac-3S relies on non-linear optical interactions to perform entropy quantum computing at ambient room temperature. The platform processes continuous and discrete variables to explore constrained optimization landscapes. In this deployment, parallel benchmarking runs will evaluate whether the optical approach provides improvements in sampling efficiency, clustering quality, or reproducibility when compared with classical solvers.
The business structure centers on identifying indications that qualify for expedited regulatory review paths, enabling the biotech partner to structure capital-efficient clinical protocols. The contract establishes a baseline discovery framework that can be expanded to future candidate pipelines.
Official release details are available from Quantum Computing Inc. here.
Novemebr 11 2026
In GQI Portal
The players behind the news
The team that writes QCR tracks every company, deal and technology in the GQI Factory, GQI's verified database of the quantum industry. Next up: every story linked to its players, coming to QCR's paid plans.
- Players Companies and institutions across the quantum industry, by segment.
- Scorecards How the players compare on hardware, software, funding and more.
Newsletter
QCR Alerts in your inbox
The latest reporting and analysis from Quantum Computing Report. Free, unsubscribe any time.